---
title: "Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284221082.md"
description: "Seaport Therapeutics, a Boston-based biotech firm focused on neuropsychiatric therapies, has announced terms for its $201 million IPO, planning to offer 11.8 million shares priced between $16 and $18. The company, founded in 2024, is developing oral therapies for conditions like depression and anxiety using its proprietary Glyph platform. Its lead programs include GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Seaport plans to list on Nasdaq under the symbol SPTX, with pricing expected the week of April 27, 2026."
datetime: "2026-04-27T13:00:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284221082.md)
  - [en](https://longbridge.com/en/news/284221082.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284221082.md)
generator: "portal-rs"
---

# Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week

Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday.

The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. 

Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions. The company uses its proprietary Glyph platform, a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism, to reformulate clinically validated mechanisms into differentiated product candidates. Its lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates targeting depressive and related CNS disorders.

Seaport Therapeutics was founded in 2024. It plans to list on the Nasdaq under the symbol SPTX. Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal. It is expected to price the week of April 27, 2026.

### Related Stocks

- [SEEL.US](https://longbridge.com/en/quote/SEEL.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Has the bull market shifted to biotech stocks?](https://longbridge.com/en/news/293077044.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**